Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 2

3(33.3%)

Phase 3

1(11.1%)

9Total

Phase 1(5)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07501208Phase 1Withdrawn

Dendritic Cell Vaccine to Prevent COVID-19

Role: collaborator

NCT04386252Phase 1Withdrawn

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults

Role: lead

NCT05100641Phase 3Not Yet Recruiting

AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM

Role: lead

NCT03743298Phase 1Recruiting

Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

Role: lead

NCT02033616Phase 2Unknown

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas

Role: lead

NCT03400917Phase 2Unknown

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma

Role: lead

NCT04690387Phase 1Completed

Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection

Role: lead

NCT05007496Phase 2Completed

Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19

Role: lead

NCT04685603Phase 1Unknown

Dendritic Cell Vaccine to Prevent COVID-19

Role: collaborator

All 9 trials loaded